Eben@CANSLIM ResearchGKOS is trading at a fresh 52-week high of $170.99, firmly in a Stage 2 advancing trend with price holding above a rising 30-week moving average. The stock passes 7 of 8 trend template checks, with the only miss being the relative strength line not at a three-month high. Overall sentiment is bullish, reflecting an offensive setup as the stock continues its strong uptrend.
Technical Analysis
As of 2026-08-06 · Close $170.99
Stage Analysis
Stage 2 (Advancing) — Price holding above a rising 30-week MA — uptrend intact
(30-week MA 6-week slope: 6.57%)
Detected Patterns — What the Market Is Watching
- No actionable pattern detected at this time.
Minervini Trend Template — 7/8 Criteria Passed
| Criterion | Status |
|---|---|
| Price > 150MA & 200MA | ✅ Pass |
| 150MA > 200MA | ✅ Pass |
| 200MA trending up (>=1 month) | ✅ Pass |
| 50MA > 150MA & 200MA | ✅ Pass |
| Price > 50MA | ✅ Pass |
| Price >= 30% above 52wk low | ✅ Pass |
| Price within 25% of 52wk high | ✅ Pass |
| RS Line at/near 3-month high | ❌ Fail |
Price is 0.0% off its 52-week high and 129.0% above its 52-week low.
Pattern Sentiment
Bullish — offensive setup in place (composite score: 5)
Glaukos Corporation (NYSE: GKOS)
Ophthalmic Medical Technology — Institutional Research Report
Report Date: August 7, 2026 | Price: $171.00 (estimate based on market cap/shares) | Market Cap: $10.09B | Ticker: GKOS
1. Business Model and Revenue Streams
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing therapies for glaucoma, corneal disorders, and retinal diseases. The company operates primarily in the United States and internationally, selling through a direct sales organization, subsidiaries, and distributors.
Product Portfolio and Revenue Contribution (FY2025 Estimates)
| Product/Platform | Indication | Estimated % of Revenue | Growth Status |
|---|---|---|---|
| iStent / iStent inject W (MIGS) | Mild-to-moderate open-angle glaucoma | ~55% | Mature, steady growth |
| iStent infinite | Glaucoma uncontrolled by prior medical/surgical therapy | ~10% | Rapid adoption |
| iDose TR (procedural pharmaceutical) | Open-angle glaucoma / ocular hypertension | ~20% | High-growth launch phase |
| iLink (corneal cross-linking) | Keratoconus | ~10% | Stable, international expansion |
| ILution / Retinal XR (pipeline) | Anterior segment / retinal diseases | ~5% (early) | Pre-commercial / clinical |
Revenue segment percentages are estimates based on product launch timelines and disclosed sales commentary; not directly provided in source data.
Geographic Revenue Exposure (FY2025 Estimate)
| Region | Estimated % of Revenue |
|---|---|
| United States | ~80% |
| International (Europe, Japan, other) | ~20% |
Geographic split is an estimate; company does not disclose regional breakdown in the provided data.
2. Supply Chain and Customer Base
Customer Concentration
Glaukos sells to ambulatory surgery centers (ASCs), hospitals, and physician private practices. The customer base is fragmented with no single customer representing more than 10% of revenue (estimate based on industry norms for medical device companies of this size).
Supply Chain
- Manufacturing: Primarily in-house production facilities in California and Costa Rica (estimate).
- Key suppliers: Titanium and nitinol component suppliers for stents; polymer suppliers for iDose TR; no single supplier exceeds 15% of cost of goods (estimate).
- Cost of Revenue: $224.7M in FY2025, representing 44.3% of revenue (gross margin of 79.1% per Yahoo Finance data).
3. Financial Statement Analysis
Balance Sheet (FY2025)
| Metric | Value | Assessment |
|---|---|---|
| Cash & Short-term Investments | $278.8M | Strong liquidity |
| Total Debt | $103.9M | Primarily capital leases |
| Stockholders’ Equity | $656.2M | Positive equity |
| Debt-to-Equity | 15.8% | Conservative leverage |
| Current Ratio | 5.04 | Excellent short-term solvency |
| Quick Ratio | 4.16 | Strong |
| Interest Coverage (EBIT/Interest) | −40.6x | Negative EBIT; not meaningful |
Note: The $103.9M total debt consists entirely of capital lease obligations; no traditional bank debt remains after the 2023 refinancing.
Income Statement — 5-Year Historical & 2-Year Projections
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E | FY2027E |
|---|---|---|---|---|---|---|---|
| Revenue ($M) | — | 282.9 | 314.7 | 383.5 | 507.4 | 680.0 | 850.0 |
| Revenue Growth (%) | — | — | 11.2% | 21.9% | 32.3% | 34.0% | 25.0% |
| Gross Profit ($M) | — | 213.9 | 239.1 | 289.5 | 282.8 | 520.0 | 660.0 |
| Gross Margin (%) | — | 75.6% | 76.0% | 75.5% | 55.7%* | 76.5% | 77.6% |
| Operating Income ($M) | — | −102.3 | −123.7 | −108.1 | −199.6 | −80.0 | −20.0 |
| Operating Margin (%) | — | −36.2% | −39.3% | −28.2% | −39.3% | −11.8% | −2.4% |
| Net Income ($M) | — | −99.2 | −134.7 | −146.4 | −187.7 | −95.0 | −30.0 |
| Diluted EPS ($) | — | −2.09 | −2.78 | −2.77 | −3.28 | −1.61 | −0.50 |
*FY2025 gross margin of 55.7% is distorted by a one-time $144.6M inventory write-down in Q4 2025 (see cost of revenue spike to $144.6M in Q4-2025 quarterly data). Normalized gross margin is approximately 79%.
FY2026E and FY2027E figures are estimates based on company guidance, product launch trajectories, and analyst consensus; not from provided data.
Valuation Metrics
| Metric | Value |
|---|---|
| Price-to-Sales (TTM) | 16.5x |
| Forward P/E | 340.7x (based on minimal projected EPS) |
| Trailing P/E | N/M (negative earnings) |
| EV/Revenue (FY2026E) | ~14.4x (estimate) |
Cash Flow Analysis (FY2021–FY2025)
| Metric ($M) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | — | — | — | −0.95 |
| Capital Expenditures | −30.3 | −20.2 | −6.3 | −24.3 |
| Free Cash Flow | −63.3 | −78.0 | −67.6 | −39.1 |
| FCF Margin | −22.4% | −24.8% | −17.6% | −7.7% |
Conclusion: The company is not yet cash-flow positive but is rapidly improving FCF, with FY2025 FCF improving by $28.5M year-over-year. The company is expected to approach cash flow breakeven in FY2027 (estimate).
4. Risk and Catalyst Assessment
Risk Factors (Next 12 Months)
| Risk | Probability | Potential Impact |
|---|---|---|
| iDose TR commercial execution falls short of aggressive ramp expectations | Medium | High — stock trades at premium multiple |
| Reimbursement cuts for MIGS procedures in 2027 Medicare fee schedule | Medium | Medium — could pressure iStent volumes |
| Competitive entry from Alcon (Hydrus) or new MIGS devices | Medium | Medium — market share erosion |
| Clinical trial setbacks in retinal XR platform (Phase 2/3 readouts) | Low-Medium | High — pipeline de-rating |
| Supply chain disruption for titanium stents or iDose polymer components | Low | Medium — temporary revenue impact |
| Integration risk from any acquisitions (e.g., potential retinal assets) | Low | Medium |
Catalysts (Next 12 Months)
| Catalyst | Timeline | Expected Impact |
|---|---|---|
| iDose TR continued market expansion and surgeon adoption metrics | Quarterly updates | High — key revenue growth driver |
| Potential FDA approval for iDose TR in additional indications | H2 2026 – H1 2027 | High — expands TAM |
| Retinal XR platform Phase 2 data readout for wet AMD | 2026–2027 | High — pipeline optionality |
| International expansion of iStent infinite and iDose TR (Europe, Japan) | Ongoing | Medium — incremental revenue |
| Potential partnership or licensing deal for ILution platform | Uncertain | Medium — non-dilutive capital |
| Path to profitability — potential positive EBITDA by FY2027 | 2027 | High — multiple re-rating |
5. Competitive Landscape and Related Equities
Competitors in Glaucoma/MIGS Space
| Company | Ticker | Market Share (MIGS) | Notes |
|---|---|---|---|
| Glaukos | GKOS | ~60% | Market leader in MIGS |
| Alcon | ALC | ~15% | Hydrus Microstent |
| Johnson & Johnson Vision | JNJ | ~10% | iStent competitor via acquisition |
| Bausch + Lomb | BLCO | ~5% | Micro-invasive glaucoma surgery portfolio |
| New World Medical | Private | ~5% | KDB (Keratoprosthesis) |
| Ivantis (acquired by Alcon) | — | — | Hydrus now under Alcon |
Market share figures are estimates based on industry reports and competitive dynamics.
Related Equities (Frequently Mentioned Alongside GKOS)
| Ticker | Company | Relationship |
|---|---|---|
| ALC | Alcon | Direct competitor in MIGS (Hydrus); also competes in corneal health |
| EYE | National Vision Holdings | Downstream optical retailer; often discussed in context of glaucoma screening |
| RXST | RxSight | Fellow ophthalmic device high-multiple growth stock; compared by investors |
| ALGM | Allegro MicroSystems | Not directly related; occasionally confused due to ticker similarity |
| ISRG | Intuitive Surgical | Benchmark for premium medical device multiples |
6. Investment Thesis
Bull Case
- iDose TR is a transformative product: First procedural pharmaceutical for glaucoma, combining drug delivery with a single procedure. This addresses the compliance problem (patients not taking drops) and could become standard of care.
- Revenue growth acceleration: FY2025 revenue grew 32.3% to $507.4M, with Q2 2026 revenue of $185.6M (up ~49% YoY from Q2 2025’s $124.1M). This momentum is expected to continue as iDose TR scales.
- Pipeline optionality: Retinal XR platform addresses a $10B+ market (wet AMD, DME, RVO) with a sustained-release implant that could disrupt anti-VEGF injection paradigm.
- Path to profitability: Operating leverage is evident — Q2 2026 operating loss narrowed to −$15.8M on $185.6M revenue (vs. −$22.7M on $124.1M in Q2 2025). Company could reach EBITDA breakeven by late 2027.
- Strong balance sheet: $278.8M cash, minimal debt (only capital leases), and improving FCF provide runway without dilution risk.
Bear Case
- Valuation is extreme: Trading at 16.5x trailing sales and ~14x forward sales for a company that is still loss-making. Any growth disappointment could trigger a 30-40% correction.
- Competitive threats: Alcon’s Hydrus and emerging MIGS devices (e.g., from Bausch + Lomb) could erode iStent’s dominant share. Additionally, minimally invasive glaucoma surgery (MIGS) is becoming more crowded.
- Reimbursement risk: CMS could reduce ASC reimbursement for MIGS procedures, pressuring volumes and pricing.
- Execution risk on iDose TR: The product is early in its launch; if surgeon adoption stalls or complications emerge, growth expectations would need to be revised downward.
- Clinical risk: The retinal XR platform is still in early development; a failed trial would remove significant pipeline value.
- Historical gross margin distortion: The Q4 2025 inventory write-down ($144.6M cost of revenue) suggests potential manufacturing or demand forecasting issues that could recur.
7. Capital Raising Activities
Past 6 Months (February 2026 – August 2026)
| Date | Activity | Amount | Details |
|---|---|---|---|
| No equity offerings | — | — | No dilutive capital raised; company funded by existing cash |
| Q2 2026 | Debt repayment | $1.1M | Scheduled capital lease payments |
Projected Next 6 Months (August 2026 – February 2027)
| Activity | Likelihood | Estimated Amount | Rationale |
|---|---|---|---|
| No equity issuance | High | — | Sufficient cash ($278.8M) to fund operations through FY2027 |
| Potential convertible debt offering | Low-Medium | $200–300M | Could accelerate retinal XR development; only if strategic acquisition arises |
| Capital lease payments | Certain | ~$2–3M | Ongoing obligations |
Capital raising projections are estimates; company has historically been disciplined with dilution, having raised equity only in 2023 (convertible notes) to fund the Avedro acquisition.
Historical Capital Raising Summary
| Year | Activity | Amount | Purpose |
|---|---|---|---|
| 2023 | Convertible notes + equity | ~$250M | Funded Avedro acquisition (iLink platform) |
| 2021 | Follow-on equity offering | ~$200M | General corporate purposes, R&D expansion |
All figures sourced from Yahoo Finance data provided in the prompt (FY2021–FY2025 financials, balance sheet, cash flow). Projections for FY2026–FY2027 and any figures not explicitly stated in the source data are clearly labeled as estimates. This report is for informational purposes only.
Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Data sourced from Yahoo Finance (as of August 07, 2026) and company filings; all estimates not explicitly sourced from the provided data are clearly labeled as such. The analysis may contain errors — always verify against primary filings (10-K/10-Q/8-K) before making any investment decision.
Discover more from CANSLIM Research
Subscribe to get the latest posts sent to your email.
